Skip to content

Er:YAG laser combined with Hyaluronic acid in the treatment of peri-implantitis: A rondomized clinical trial

Er:YAG laser combined with Hyaluronic acid in the treatment of peri-implantitis: A rondomized clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900026515
Enrollment
Unknown
Registered
2019-10-13
Start date
2019-10-01
Completion date
Unknown
Last updated
2019-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

peri-implantitis

Interventions

Group 1:use vector ultrasonic therapy to treat the tested implant
Group 2:use Er:YAG to treat the tested implant
Group 3:use Er: YAG combined with local application of HA to treat the tested implant

Sponsors

Stomatological Center of Haikou People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. the patient who visit outpatient department of implantation and comprehensive treatment in stomatology center of Haikou people's hospital; 2. a minimum of one osseointegrated implant with early peri-implantitis,which means that compared with the baseline, the infected implant is with bleeding and/or pus on probing,increase of the probing depth limited to 4mm(using 0.2 N probing force), loss of bone limited to 50% of length of the implant; 3. the percentage of full mouth plaque index is less than 25%; 4. the percentage of full mouth bleeding on probing is less than 25%; 5. understanding and signing the informed consent.

Exclusion criteria

Exclusion criteria: 1. exacerbation of periodontitis; 2. allergic to HA gel; 3. during pregnancy or lactation; 4. used antibiotics in the past 3 months; 5. received more than two weeks of medication (such as phenytoin sodium, calcium antagonists, cyclosporine, coumarin and non-steroidal anti-inflammatory drugs) that affected periodontal soft tissue examination in the past month; 6. suffering from other uncontrollable systemic diseases (diabetes, etc.); 7. participating in other clinical trials; 8. implant loosening, sinus formation, occlusal trauma.

Design outcomes

Primary

MeasureTime frame
mSBI;

Secondary

MeasureTime frame
mPLI;PD;SOP;AL;MTR;MBL;VD;DR;DF;DPD;

Countries

China

Contacts

Public ContactXupu

Stomatological Center of Haikou People's Hospital

hnxupu@163.com+86 13807699863

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026